Drug intelligence / Profile preview

Zocobin Plus

Development stage
Unknown
Lead developer
MTI Medical
Modality
Small Molecules
Administration
Oral
01

Overview

Zocobin Plus is a neurotropic combination therapy developed and marketed by MTI Medical, primarily used for the management of peripheral neuropathies, including diabetic neuropathy. It contains mecobalamin (a coenzyme form of vitamin B12), alpha lipoic acid (a potent antioxidant), folic acid, and pyridoxine (vitamin B6). Mecobalamin facilitates nerve regeneration by promoting myelin sheath formation through methionine synthase activation. Alpha lipoic acid reduces oxidative stress and improves endoneurial blood flow, while folic acid and pyridoxine support essential metabolic processes and neurotransmitter synthesis. Together, these components work synergistically to alleviate symptoms such as numbness, tingling, and pain associated with nerve damage.

Brand names
Zocobin PlusZocobin Plus-MTI Medical
Other names
Mecobalamin + Alpha Lipoic Acid + Folic Acid + Pyridoxine
02

Targets

DDC (Aromatic L-amino acid decarboxylase)MTR (Methionine synthase)DHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on Zocobin Plus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zocobin Plus.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call